Codabakalner's ASD Bet: Biomarker Logic Is Sound, But Evidence Base Is Dangerously Thin

Spinogenix Expands CLARITY Trial for Autism with Biomarker-Enriched Phase 2b

Spinogenix announced the expansion of its Phase 2b/3 CLARITY basket trial (NCT07439510) to include a Phase 2b study in idiopathic autism spectrum disorder (ASD). This new study will evaluate codabakalner (SPG601) using a novel biomarker-enriched enrollment design, selecting participants whose electroencephalogram (EEG) shows elevated resting gamma band power. This approach is based on findings from Fragile X syndrome (FXS), where codabakalner previously reduced gamma power and improved executive function. A study co-authored by Spinogenix found that 22% of autism participants, and 31.9% of adults, exhibit this FXS-like gamma signature, suggesting a targeted treatment strategy for a specific subgroup within the heterogeneous ASD population.

• The CLARITY trial's Phase 2b study for idiopathic ASD will employ a novel biomarker enrichment strategy. Instead of relying solely on observable clinical criteria, participants will be selected based on an electroencephalogram (EEG) showing elevated resting gamma band power. This approach aims to target a specific biological subgroup within the highly heterogeneous autism population, increasing the likelihood of demonstrating therapeutic benefit for codabakalner (SPG601).
• The biomarker-driven approach is informed by parallels between idiopathic ASD and Fragile X syndrome (FXS), a common genetic cause of autism where elevated resting gamma power is a robust brain finding. A prior Phase 2a study demonstrated that codabakalner reduced gamma power in adult men with FXS, correlating with significant improvements in executive function and selective attention, providing a strong rationale for testing this hypothesis in the identified ASD subgroup.
• Research co-authored by Spinogenix identified a distinct subgroup within the autism spectrum. A study comparing EEGs of 159 people with autism to those with FXS found that 22% of autism participants (rising to 31.9% in adults) exhibited the same elevated gamma signature seen in FXS. Crucially, this subgroup showed no readily observable clinical differences from others with autism, highlighting the necessity of a biomarker-based approach for targeted treatment development.

Addressing Heterogeneity: The Challenge in Autism Spectrum Disorder Treatment

The management of idiopathic ASD is complicated by the absence of any FDA-approved pharmacotherapy targeting core social-communication deficits, combined with the profound clinical and etiological heterogeneity that characterizes the condition. Current treatment strategies remain largely symptom-directed, with efficacy concentrated in specific patient subgroups and burdened by clinically significant adverse effect profiles.

• No approved treatment for core symptoms: No drug is FDA-approved for the core social-communication deficits of ASD. The only FDA-approved pharmacological agents — risperidone and aripiprazole — are indicated solely for irritability and aggression, not for the defining features of the disorder. Selective serotonin reuptake inhibitors are not effective in improving repetitive behaviors in children with ASD and frequently cause activating adverse events. Efficacy of antiepileptic drugs is inconclusive.

• Metabolic and safety burden of approved antipsychotics: Risperidone carries a greater metabolic burden than aripiprazole, including weight gain, elevated liver enzymes, extrapyramidal side effects, and metabolic syndrome. In a 24-week trial of risperidone in children with ASD (mean age 6.9 years), mean weight gain was 5.4 ± 3.4 kg; waist circumference increased from 60.7 ± 10.4 cm to 66.8 ± 11.3 cm; and significant increases were observed in glucose, hemoglobin A1c, insulin, HOMA-IR, alanine aminotransferase, and leptin, while adiponectin declined. At baseline, 7 children met conventional criteria for metabolic syndrome; by week 16, 12 additional children were so classified. A network meta-analysis further confirmed that atypical antipsychotics as a class are associated with a significantly higher risk of weight gain (RR 2.40, 95% CI 1.25 to 4.60; very low-certainty evidence) and extrapyramidal side effects (RR 2.36, 95% CI 1.22 to 4.59; very low-certainty evidence) compared to placebo.

• Phenotypic and etiological heterogeneity limiting treatment generalizability: The tremendous clinical and etiological variability between individuals with ASD means that the efficacy of interventions is highly variable and concentrated in specific patient subgroups. Emerging therapies illustrate this directly: microbiota transfer therapy showed significant improvement in GI and behavioral symptoms specifically in cohorts with GI disease, and high-dose folinic acid efficacy was concentrated in the subgroup with folate receptor-α autoantibodies. Without validated stratification biomarkers, it remains impossible to reliably predict which patients will respond to a given intervention.

• Absence of validated stratification biomarkers: Despite large-scale multi-centre observational efforts — such as the EU-AIMS LEAP study, which enrolled 437 individuals with ASD and 300 typically developing or mildly intellectually disabled individuals — no single validated stratification biomarker for ASD has been identified. Most prior research focused on mean case-control differences rather than within-group variability, and included samples underpowered for stratification approaches.

• Limitations of behavioral interventions and access barriers: ABA-based interventions show significant improvements in adaptive behavior (SMD = 0.31, 95% CI: 0.04–0.59, GRADE = low), daily living skills (SMD = 0.36, 95% CI: 0.08–0.64, GRADE = low), language skills (SMD = 0.42, 95% CI: 0.24–0.60, GRADE = moderate), and joint attention behavior (SMD = 0.27, 95% CI: 0.04–0.49, GRADE = low), but the quality of evidence is generally low to very low, most studies carry a high risk of bias, and effects on core autism symptoms are more variable. Systemic barriers — including financial constraints, variability in training quality, insurance denials, geographic limitations, and ABA workforce shortages — further restrict access to these interventions.

• Variability in pharmacotherapy tolerability relative to neurotypical populations: Overall, efficacy and tolerability of pharmacotherapy in children with ASD are less favorable than data seen in typically developing children with similar symptoms. Higher risperidone sum trough concentrations predict higher BMI z-scores, more sedation, and higher prolactin levels, suggesting a therapeutic window exists but is difficult to manage without therapeutic drug monitoring — an approach not yet established as standard practice.

• Failed clinical trials and translational gaps in precision medicine: Several recently failed clinical trials with syndromic forms of ASD have highlighted limitations in the translatability from animal models to humans, placebo effects, and the need for mechanistically plausible, objective outcome measures. Future research must prioritize validation of biological biomarkers — metabolic, genetic, and neurophysiological — to reliably predict treatment response and guide selection of targeted therapies.

CLARITY's Novel EEG Biomarker Strategy for Autism Spectrum Disorder

In the randomized, double-blind, placebo-controlled, 2-period balanced crossover study of SPG601 conducted in 10 adult men with genetically confirmed full-mutation fragile X syndrome (FXS), patient selection was anchored to genetic confirmation of diagnosis, restricting enrollment to individuals with a molecularly verified full mutation. This genotype-based selection strategy ensured a biologically homogeneous population in whom the mechanistic rationale for SPG601 — restoring synaptic function by correcting BK channel dysfunction downstream of fragile X messenger ribonucleoprotein protein (FMRP) loss — was directly applicable.

The primary neurophysiologic biomarker strategy centered on resting-state EEG power spectral density, with excessive high-frequency gamma band activity designated as the primary neurophysiologic endpoint. This selection was grounded in its extensive cross-species validation as a biomarker in FXS and its demonstrated correlation with severity of the human FXS phenotype. Additional EEG endpoints included alpha2 power, theta power, aperiodic EEG slope (reflecting excitation-inhibition balance via the broadband 1/f component), and auditory-evoked gamma oscillations, providing a multi-band neurophysiologic characterization of treatment response.

Cognitive assessment was incorporated as a secondary patient-level outcome strategy, using the NIH Toolbox Flanker Inhibitory Control and Attention Test to capture executive function. Safety and tolerability were evaluated as a primary outcome given the first-in-FXS nature of the study, and clinical global impressions scales were also employed. Together, these strategies combined genotype-defined patient selection with a validated electrophysiologic biomarker framework and standardized cognitive instruments to characterize both neurophysiological and functional responses to SPG601.

Codabakalner's Journey: From Fragile X to Idiopathic Autism Spectrum Disorder

The knowledge base does not have sufficient information to answer this question.

A Precision Approach to Autism Spectrum Disorder Treatment

The expansion of Spinogenix's CLARITY trial to include idiopathic autism spectrum disorder (ASD) represents a pivotal moment in the pursuit of more effective treatments for this complex condition. Recognizing the profound heterogeneity of ASD, the company is adopting a precision medicine approach, focusing on a specific subgroup of patients identified by a novel biomarker: elevated resting gamma band power on electroencephalogram (EEG).

This strategy is deeply rooted in the understanding of Fragile X syndrome (FXS), a monogenetic cause of intellectual disability and autism, where cortical hyperexcitability and increased gamma power are well-documented neurophysiological features. Codabakalner (SPG601), a BK channel activator, has previously shown promise in FXS by reducing this excessive gamma activity and improving executive function. The inference is that a subset of idiopathic ASD patients, exhibiting a similar 'FXS-like gamma signature' (estimated at 22% of all ASD patients and 31.9% of adults), may share a common underlying pathophysiology and thus be responsive to the same therapeutic mechanism.

This targeted development approach offers several strategic advantages. It aims to de-risk clinical trials by focusing on a patient population with a higher likelihood of response, potentially accelerating the path to regulatory approval. Success would further validate EEG gamma power as a crucial translational biomarker, not just for FXS but also for a specific endophenotype within idiopathic ASD, opening doors for its use in other neurodevelopmental disorders characterized by similar neural hyperexcitability. Commercially, this could allow codabakalner to establish a distinct market niche, addressing a specific biological mechanism within the broader ASD landscape.

However, this innovative path is not without its considerations. The identified subgroup, while biologically defined, represents a fraction of the total ASD population, which could limit the drug's overall market potential. While the scientific rationale for translating FXS findings to this ASD subgroup is strong, the actual clinical efficacy in idiopathic ASD still requires robust validation. Furthermore, the practicalities of implementing a biomarker-driven enrollment, requiring specialized EEG diagnostics, could pose challenges for patient identification and recruitment in both clinical trials and future commercial settings. Despite these considerations, this biomarker-driven strategy for codabakalner signifies a promising shift towards more individualized and effective treatments for neurodevelopmental disorders.